NASDAQ: PRMEPrime Medicine Inc Stock Ownership - Who owns Prime Medicine?
Insider buying vs selling
Have Prime Medicine Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David R. Liu | 10% Owner | 2025-06-30 | 21,000 | $2.52 | $52.84kBuy |
| David R. Liu | 10% Owner | 2025-06-23 | 21,000 | $2.16 | $45.40kBuy |
| David R. Liu | 10% Owner | 2025-06-16 | 21,000 | $1.49 | $31.21kBuy |
| David R. Liu | 10% Owner | 2025-06-11 | 21,000 | $1.60 | $33.58kBuy |
| Ann L. Lee | Chief Technical Officer | 2025-05-21 | 100,000 | $1.13 | $113.00kBuy |
| Allan Reine | Chief Executive Officer | 2025-05-21 | 125,000 | $1.18 | $147.13kBuy |
| Richard Brudnick | Chief Business Officer | 2025-05-20 | 20,000 | $1.19 | $23.80kBuy |
PRME insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PRME insiders and whales buy or sell their stock.
PRME Shareholders
What type of owners hold Prime Medicine Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| David R. Liu | 15.42% | 20,240,945 | $88.05M | Insider |
| Robert Nelsen | 11.78% | 15,472,674 | $67.31M | Insider |
| Arch Venture Partners X LLC | 11.77% | 15,456,594 | $67.24M | Insider |
| Arch Venture Partners XII LLC | 11.77% | 15,456,594 | $67.24M | Insider |
| Alphabet Inc | 11.47% | 15,062,498 | $65.52M | Institution |
| Gv 2019 GP LLC | 9.04% | 11,862,498 | $51.60M | Insider |
| Fmr LLC | 6.45% | 8,462,946 | $36.81M | Insider |
| Keith Michael Gottesdiener | 4.15% | 5,451,894 | $23.72M | Insider |
| Thomas Cahill | 4.04% | 5,305,679 | $23.08M | Insider |
| Blackrock Inc | 3.28% | 4,306,211 | $18.73M | Institution |
PRME vs Biotech Stocks
Prime Medicine Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.